GSK touts co-administration data for RSV, shingles vaccines as narrowed CDC guidance threatens sales

This summer, GSK cut its yearly vaccine sales projection on the back of a narrowed recommendation for adult respiratory syncytial virus (RSV) vaccines from the Centers for Disease Control and Prevention. With sales of its flagship shingles vaccine Shingrix separately faltering, new data on co-administration of the two adult vaccines could provide a new way for the company to promote the jabs.